Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) CEO Joseph Truitt Sells 133,484 Shares

Share on StockTwits

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) CEO Joseph Truitt sold 133,484 shares of the business’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $6.37, for a total value of $850,293.08. Following the completion of the sale, the chief executive officer now directly owns 103,734 shares of the company’s stock, valued at $660,785.58. The sale was disclosed in a legal filing with the SEC, which is available through this link.

ACHN traded down $0.11 during midday trading on Friday, reaching $6.09. 6,386,438 shares of the company were exchanged, compared to its average volume of 1,961,746. The company’s fifty day moving average price is $4.01 and its 200 day moving average price is $3.45. The company has a market cap of $509.88 million, a price-to-earnings ratio of -11.94 and a beta of 1.57. Achillion Pharmaceuticals, Inc. has a one year low of $1.29 and a one year high of $6.44.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, hitting analysts’ consensus estimates of ($0.14). On average, sell-side analysts forecast that Achillion Pharmaceuticals, Inc. will post -0.59 EPS for the current year.

A number of analysts recently commented on the company. Svb Leerink lowered Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating and boosted their target price for the company from $5.00 to $6.30 in a research report on Friday. BidaskClub lowered Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 12th. Leerink Swann lowered Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday. Zacks Investment Research lowered Achillion Pharmaceuticals from a “hold” rating to a “sell” rating and set a $4.75 target price for the company. in a research report on Tuesday, August 27th. Finally, ValuEngine raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. Achillion Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $4.52.

A number of institutional investors and hedge funds have recently modified their holdings of ACHN. MetLife Investment Advisors LLC bought a new stake in Achillion Pharmaceuticals during the 1st quarter worth approximately $200,000. Metropolitan Life Insurance Co NY bought a new stake in Achillion Pharmaceuticals during the 1st quarter worth approximately $131,000. SG Americas Securities LLC bought a new stake in Achillion Pharmaceuticals during the 2nd quarter worth approximately $97,000. DekaBank Deutsche Girozentrale increased its holdings in Achillion Pharmaceuticals by 63.8% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 108,600 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 42,300 shares in the last quarter. Finally, Swiss National Bank increased its holdings in Achillion Pharmaceuticals by 21.3% during the 2nd quarter. Swiss National Bank now owns 245,100 shares of the biopharmaceutical company’s stock worth $657,000 after purchasing an additional 43,000 shares in the last quarter. 78.57% of the stock is owned by hedge funds and other institutional investors.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

See Also: How are dividend achievers different from dividend aristocrats?

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Tapestry Inc  Shares Bought by Financial Architects Inc
Tapestry Inc Shares Bought by Financial Architects Inc
Brokerages Expect United Insurance Holdings Corp  to Announce $0.32 Earnings Per Share
Brokerages Expect United Insurance Holdings Corp to Announce $0.32 Earnings Per Share
$0.55 Earnings Per Share Expected for PBF Energy Inc  This Quarter
$0.55 Earnings Per Share Expected for PBF Energy Inc This Quarter
Zacks: Brokerages Anticipate Health Insurance Innovations Inc  Will Post Earnings of $2.42 Per Share
Zacks: Brokerages Anticipate Health Insurance Innovations Inc Will Post Earnings of $2.42 Per Share
Matson  Stock Rating Lowered by Zacks Investment Research
Matson Stock Rating Lowered by Zacks Investment Research
Forty Seven  Rating Reiterated by Mizuho
Forty Seven Rating Reiterated by Mizuho


© 2006-2019 Ticker Report